Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CASP6 | P55212 | 2/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297761 | 0.87 | ATM (0.40) | ATMTDP1ALDH1A1HIF1ALMNA | |
| SCHEMBL31558555 | 0.86 | CYP1A2 (0.45) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL6583252 | 0.86 | CYP1A2 (0.45) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL16418206 | 0.85 | CYP1A2 (0.44) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL16418207 | 0.85 | CYP1A2 (0.44) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL6284211 | 0.81 | GPR35 (0.44) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL6284204 | 0.81 | GPR35 (0.44) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL6179100 | 0.80 | TDP1 (0.44) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL4201072 | 0.79 | ATM (0.42) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL3138102 | 0.79 | GPR35 (0.46) | CYP1A2TDP1ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| EP-1943230-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20090318431-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| EP-1987025-B1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PROD INC (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1987025-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pfizer Products Incorporated (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1943230-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2007121416-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | WO | disclosed |
| US-6900231-B2 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1324981-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6521663-B2 | For oral administration or embedded or otherwise attached to medical devices for blood collection and/or treatment | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS | 2002-05-23 | — | — | US | disclosed |
| WO-2002028825-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-0470578-B1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KK (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5399553-A | Oral absorbability | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1995-03-21 | — | — | US | disclosed |
| US-5254685-A | Tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0470578-A1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | CYP1A2 393/4885ATM 2225/4885TDP1 2576/4885 |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | CHRM1, CHRM2, CHRM5 | CYP1A2 460/4885ATM 2013/4885TDP1 2127/4885 |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | TFPI, PLG, PLAT | CYP1A2 3303/4885ATM 1077/4885TDP1 1398/4885 |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | TFPI, F12, PLAT | CYP1A2 2955/4885ATM 864/4885TDP1 1312/4885 |
| US-20090318431-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | HRH2, HRH1, HRH4 | CYP1A2 314/4885ATM 4680/4885TDP1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.